These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 22399571)

  • 1. Attention-deficit/hyperactivity disorder among children and adolescents in the United States: trend in diagnosis and use of pharmacotherapy by gender.
    Sclar DA; Robison LM; Bowen KA; Schmidt JM; Castillo LV; Oganov AM
    Clin Pediatr (Phila); 2012 Jun; 51(6):584-9. PubMed ID: 22399571
    [No Abstract]   [Full Text] [Related]  

  • 2. Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in Medicaid database.
    Winterstein AG; Gerhard T; Shuster J; Zito J; Johnson M; Liu H; Saidi A
    Ann Pharmacother; 2008 Jan; 42(1):24-31. PubMed ID: 18042808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacotherapy for child and adolescent attention-deficit hyperactivity disorder.
    Kaplan G; Newcorn JH
    Pediatr Clin North Am; 2011 Feb; 58(1):99-120, xi. PubMed ID: 21281851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment stabilization in children and adolescents with attention-deficit/hyperactivity disorder: data from the Netherlands.
    Sasané R; Hodgkins P; Meijer W
    Curr Med Res Opin; 2010 Nov; 26(11):2565-74. PubMed ID: 20863165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Without treatment the crash threatens].
    Einecke U
    MMW Fortschr Med; 2009 Jan; 151(5):14-6. PubMed ID: 19391404
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacologic treatment of attention-deficit/hyperactivity disorder in children: incidence, prevalence, and treatment patterns in the Netherlands.
    Hodgkins P; Sasané R; Meijer WM
    Clin Ther; 2011 Feb; 33(2):188-203. PubMed ID: 21497704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological management of a youth with ADHD and a seizure disorder.
    Gonzalez-Heydrich J; Weiss M; Connolly M; Wambera K; Jan JE; Plioplys S; Dunn DW; Kratochvil CJ
    J Am Acad Child Adolesc Psychiatry; 2006 Dec; 45(12):1527-32. PubMed ID: 17135999
    [No Abstract]   [Full Text] [Related]  

  • 8. Diagnosis and management of attention-deficit/hyperactivity disorder in children, young people, and adults: summary of NICE guidance.
    Kendall T; Taylor E; Perez A; Taylor C;
    BMJ; 2008 Sep; 337():a1239. PubMed ID: 18815170
    [No Abstract]   [Full Text] [Related]  

  • 9. [Update on Current Care guidelines: ADHD (attention-deficit/hyperactivity disorder, children and adolescents)].
    Käypä hoito suosituksen päivitystiivistelmä
    Duodecim; 2012; 128(5):539-40. PubMed ID: 22486070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Attention deficit hyperactivity disorder: part III.
    Ryan-Krause P
    J Pediatr Health Care; 2011; 25(1):50-6. PubMed ID: 21147408
    [No Abstract]   [Full Text] [Related]  

  • 11. Attention-deficit-hyperactivity disorder: an update.
    Dopheide JA; Pliszka SR
    Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving decision making in the treatment of ADHD.
    Vitiello B
    Am J Psychiatry; 2008 Jun; 165(6):666-7. PubMed ID: 18519529
    [No Abstract]   [Full Text] [Related]  

  • 13. Drugs for treatment of ADHD.
    Treat Guidel Med Lett; 2006 Nov; 4(51):77-82. PubMed ID: 17039210
    [No Abstract]   [Full Text] [Related]  

  • 14. Medication options when treating children and adolescents with ADHD: interpreting the NICE guidance 2006.
    Harpin VA
    Arch Dis Child Educ Pract Ed; 2008 Apr; 93(2):58-65. PubMed ID: 18356307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atomoxetine may improve methylphenidates' efficacy in treatment of ADHD?
    Niederhofer H
    Psychiatr Danub; 2009 Sep; 21(3):330. PubMed ID: 19794351
    [No Abstract]   [Full Text] [Related]  

  • 16. National estimates and factors associated with medication treatment for childhood attention-deficit/hyperactivity disorder.
    Visser SN; Lesesne CA; Perou R
    Pediatrics; 2007 Feb; 119 Suppl 1():S99-106. PubMed ID: 17272592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular safety of ADHD medications: rationale for and design of an investigator-initiated observational study.
    Hennessy S; Schelleman H; Daniel GW; Bilker WB; Kimmel SE; Guevara J; Cziraky MJ; Strom BL
    Pharmacoepidemiol Drug Saf; 2010 Sep; 19(9):934-41. PubMed ID: 20623519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Atomoxetine in ADHD: caution].
    Karila L
    Rev Prat; 2011 Nov; 61(9 Suppl):S7-8. PubMed ID: 22338199
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacotherapy with atomoxetine for US children and adolescents.
    Bhatara VS; Aparasu RR
    Ann Clin Psychiatry; 2007; 19(3):175-80. PubMed ID: 17729019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.